China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

On March 9, Autobio released a performance report. The company's sales revenue from January to December 2021 was CNY 3.767 billion , a year-on-year increase of 26.48%.

Roche Diagnostics has launched its new molecular laboratory instrument, the cobas 5800 System, in the UK. Through improved automation, the new system can help raise testing volumes, improve operational efficiency, and manage the increasing demand that many laboratories are experiencing, Roche said.

Canadian firm MedMira said Wednesday it has obtained the CE mark for its Reveal TP (Syphilis) test, making it available in the European Union as well as other geographies that accept the designation.

Zhenzhun Biotechnology (Shanghai) Co. Ltd., a digital PCR company, has recently completed a Series A financing round of over CNY 100 million, exclusively invested by Huiyuan Capital, a professional investment institution in the healthcare industry.

A review of adverse events following vaccination against COVID-19 with mRNA vaccines in the USA confirms that most side effects were mild and decreased substantially after one day.

Luminex, a DiaSorin company, said on Tuesday that it has received CE marking for its xMap NxTag Gastrointestinal Pathogen Panel (GPP), a molecular multiplex panel for the detection of 16 different pathogens.

A new viral transport medium that enables collection and rapid inactivation of the SARS-CoV-2 virus, and stabilizes viral RNA at ambient temperature for transportation and use in in vitro diagnostic testing procedures, is now available in Europe.

Chinese single-cell technology firm Singleron Biotechnologies said on Monday that it has acquired Singapore-based Proteona.

The updated prospectus shows that Adicon additionally disclosed financial data for 2021 and other content. According to the prospectus, Adicon's operating income in 2021 will be CNY 3.380 billion.

On March 2, the FTSE Russell Day announced the results of the quarterly audit changes of the FTSE China A50 and other indices.